4-hydroxy tempo improves mitochondrial and neurobehavioral deficits in experimental model of Huntington's disease

Synapse

Volumn 69, Issue 3, 2015, Pages 128-138

  Sandhir, Rajat ^a   Mahajan, Namita ^a   Mehrotra, Arpit ^a   Aggarwal, Aanchal ^a   Sunkaria, Aditya ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

3 nitropropionic acid; 4 hydroxy tempo; Huntington's disease; Mitochondria; Neurobehavior; Oxidative stress

Indexed keywords

3 NITROPROPIONIC ACID; CATALASE; NITRITE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TEMPOL; AMINE OXIDE; HYDROXYLAMINE; SCAVENGER; TEMPOL-H;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIOR ASSESSMENT; BEHAVIOR DISORDER; BIOCHEMISTRY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DOSE REDUCTION; ENZYME ACTIVITY; FEMALE; HUNTINGTON CHOREA; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RECYCLING; RESPIRATORY CHAIN; TREATMENT DURATION; ANIMAL; COGNITION; DRUG EFFECTS; HUNTINGTON DISEASE; METABOLISM; MITOCHONDRION; MOVEMENT (PHYSIOLOGY); WISTAR RAT;

ANIMALS; CATALASE; COGNITION; CYCLIC N-OXIDES; FEMALE; FREE RADICAL SCAVENGERS; HUNTINGTON DISEASE; HYDROXYLAMINE; LIPID PEROXIDATION; MITOCHONDRIA; MOVEMENT; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE;

EID: 84921415319     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21793     Document Type: Article

References (76)

1. Aebi H. 1984. Catalase in vitro. Methods Enzymol 105:121-126.
2. Alexi T, Hughes PE, Faull RL, Williams CE. 1998. 3-Nitropropionic acid's lethal triplet: Cooperative pathways of neurodegeneration. Neuroreport 9:R57-R64.
3. Alston TA, Mela L, Bright HJ. 1977. 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc Natl Acad Sci USA 74:3767-3771.
4. Augusto O, Bonini MG, Amanso AM, Linares E, Santos CC, De Menezes SL. 2002. Nitrogen dioxide and carbonate radical anion: Two emerging radicals in biology. Free Radic Biol Med 32:841-859.
5. Barquero-Jimenez MS, Gomez-Tortosa E. 2001. Cognitive disorders in patients with Huntington's disease. Rev Neurol 32:1067-1071.
6. Becker S, Lim J. 2003. A computational model of prefrontal control in free recall: Strategic memory use in the California Verbal Learning Task. J Cogn Neurosci 15:821-832.
7. Beit-Yannai E, Zhang R, Trembovler V, Samuni A, Shohami E. 1996. Cerebroprotective effect of stable nitroxide radicals in closed head injury in the rat. Brain Res 717:22-28.
8. Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N, Saudou F, Elalouf JM, Hirsch E, Hantraye P, Deglon N, Brouillet E. 2006. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell 17:1652-1663.
9. Berridge MV, Tan AS. 1993. Characterization of the cellular reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT): Subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys 303:474-482.
10. Bizat N, Hermel JM, Boyer F, Jacquard C, Creminon C, Ouary S, Escartin C, Hantraye P, Kajewski S, Brouillet E. 2003. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. J Neurosci 23:5020-5030.
11. Brennan ML, Hazen SL. 2003. Amino acid and protein oxidation in cardiovascular disease. Amino Acids 25:365-374.
12. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF. 1997. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia. Ann Neurol 41:646-653.
13. Calabrese V, Boyd-Kimball D, Scapagnini G, Butterfield DA. 2004. Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders: The role of vitagenes. In Vivo 18:245-267.
14. Cirillo G, Maggio N, Bianco MR, Vollono C, Sellitti S, Papa M. 2010. Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats. Neurochem Int 56:152-160.
15. Cuzzocrea S, McDonald MC, Filipe HM, Costantino G, Mazzon E, Santagati S, Caputi AP, Thiemermann C. 2000. Effects of tempol, a membrane-permeable radical scavenger, in a rodent model of carrageenan-induced pleurisy. Eur J Pharmacol 390:209-222.
16. Fiske CH, Subbarow Y. 1925. The colorimetric determination of phosphorus. J Biol Chem 66:375-400.
17. Fontaine MA, Geddes JW, Banks A, Butterfield DA. 2000. Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: Insights into Huntington's disease. J Neurochem 75:1709-1715.
18. Forsmark-Andree P, Lee CP, Dallner G, Ernster L. 1997. Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles. Free Radic Biol Med 22:391-400.
19. Fujisaki K, Tsuruya K, Yamato M, Toyonaga J, Noguchi H, Nakano T, Taniguchi M, Tokumoto M, Hirakata H, Kitazono T. 2014. Cerebral oxidative stress induces spatial working memory dysfunction in uremic mice: Neuroprotective effect of tempol. Nephrol Dial Transplant 29:529-538.
20. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordelieres FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, Saudou F. 2004. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127-138.
21. Godin JD, Poizat G, Hickey MA, Maschat F, Humbert S. 2010. Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease. EMBO J 29:2433-2445.
22. Griffiths DE, Houghton RL. 1974. Studies on energy-linked reactions: Modified mitochondrial ATPase of oligomycin-resistant mutants of Saccharomyces cerevisiae. Eur J Biochem 46:157-167.
23. Guerrieri F, Capozza G, Fratello A, Zanotti F, Papa S. 1993. Functional and molecular changes in FoF1 ATP-synthase of cardiac muscle during aging. Cardioscience 4:93-98.
24. Halejcio-Delophont P, Hoshiai K, Fukuyama N, Nakazawa H. 2001. No evidence of NO-induced damage in potential donor organs after brain death. J Heart Lung Transplant 20:71-79.
25. Hamilton BF, Gould DH. 1987. Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: A type of hypoxic (energy deficient) brain damage. Acta Neuropathol 72:286-297.
26. Heinsen H, Strik M, Bauer M, Luther K, Ulmar G, Gangnus D, Jungkunz G, Eisenmenger W, Gotz M. 1994. Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol 88:320-333.
27. Howard BJ, Yatin S, Hensley K, Allen KL, Kelly JP, Carney J, Butterfield DA. 1996. Prevention of hyperoxia-induced alterations in synaptosomal membrane-associated proteins by N-tert-butyl-alpha-phenylnitrone and 4-hydroxy-2, 2, 6, 6-tetramethylpiperidin-1-oxyl (Tempol). J Neurochem 67:2045-2050.
28. Itoh J, Nabeshima T, Kameyama T. 1991. Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. Eur J Pharmacol 194:71-76.
29. Kagan VE, Jiang J, Bayir H, Stoyanovsky DA. 2007. Targeting nitroxides to mitochondria: Location, location, location, and .concentration: Highlight commentary on "Mitochondria superoxide dismutase mimetic inhibits peroxide-induced oxidative damage and apoptosis: Role of mitochondrial superoxide." Free Radic Biol Med 43:348-350.
30. Kamboj SS, Kumar V, Kamboj A, Sandhir R. 2008. Mitochondrial oxidative stress and dysfunction in rat brain induced by carbofuran exposure. Cell Mol Neurobiol 28:961-969.
31. King TE, Howard RL. 1967. Preparation and properties of soluble NADH dehydrogenase from cardiac muscle. Methods in enzymology. New York: Academic Press. p 275.
32. King TE, Ohnishi T, Winter DB, Wu JT. 1976. Biochemical and EPR probes for structure-function studies of iron sulfur centers of succinate dehydrogenase. Adv Exp Med Biol 74:182-227.
33. Kono Y. 1978. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 186:189-195.
34. Kovtun IV, Liu Y, Bjoras M, Klungland A, Wilson SH, McMurray CT. 2007. OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature 447:447-452.
35. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL. 2004. Antioxidant vitamin supplements and cardiovascular disease. Circulation 110:637-641.
36. Kwon TH, Chao DL, Malloy K, Sun D, Alessandri B, Bullock MR. 2003. Tempol, a novel stable nitroxide, reduces brain damage and free radical production, after acute subdural hematoma in the rat. J Neurotrauma 20:337-345.
37. Lafon-Cazal M, Culcasi M, Gaven F, Pietri S, Bockaert J. 1993. Nitric oxide, superoxide and peroxynitrite: putative mediators of NMDA-induced cell death in cerebellar granule cells. Neuropharmacology 32:1259-1266.
38. Lee WT, Chang C. 2004. Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: An animal model of Huntington's disease. Prog Neurobiol 72:87-110.
39. Leventhal L, Sortwell CE, Hanbury R, Collier TJ, Kordower JH, Palfi S. 2000. Cyclosporin A protects striatal neurons in vitro and in vivo from 3-nitropropionic acid toxicity. J Comp Neurol 425:471-478.
40. Liang Q, Smith AD, Pan S, Tyurin VA, Kagan VE, Hastings TG, Schor NF. 2005. Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinson's disease. Biochem Pharmacol 70:1371-1381.
41. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
42. MacGregor DG, Avshalumov MV, Rice ME. 2003. Brain edema induced by in vitro ischemia: Causal factors and neuroprotection. J Neurochem 85:1402-1411.
43. Makino A, Scott BT, Dillmann WH. 2010. Mitochondrial fragmentation and superoxide anion production in coronary endothelial cells from a mouse model of type 1 diabetes. Diabetologia 53:1783-1794.
44. Mehrotra A, Sandhir R. 2014. Mitochondrial cofactors in experimental Huntington's disease: Behavioral, biochemical and histological evaluation. Behav Brain Res 261:345-355.
45. Mozaffari MS, Baban B, Liu JY, Abebe W, Sullivan JC, El-Marakby A. 2011. Mitochondrial complex I and NAD(P)H oxidase are major sources of exacerbated oxidative stress in pressure-overloaded ischemic-reperfused hearts. Basic Res Cardiol 106:287-297.
46. Nasr P, Carbery T, Geddes JW. 2009. N-methyl-d-aspartate receptor antagonists have variable affect in 3-nitropropionic acid toxicity. Neurochem Res 34:490-498.
47. Nishino H, Shimano Y, Kumazaki M, Sakurai T. 1995. Chronically administered 3-nitropropionic acid induces striatal lesions attributed to dysfunction of the blood-brain barrier. Neurosci Lett 186:161-164.
48. Ohkawa H, Ohishi N, Yagi K. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358.
49. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. 2002. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5:731-736.
50. Perez-Pinzon MA, Xu GP, Born J, Lorenzo J, Busto R, Rosenthal M, Sick TJ. 1999. Cytochrome C is released from mitochondria into the cytosol after cerebral anoxia or ischemia. J Cereb Blood Flow Metab 19:39-43.
51. Petersen A, Castilho RF, Hansson O, Wieloch T, Brundin P. 2000. Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons. Brain Res 857:20-29.
52. Queiroz RF, Paviani V, Coelho FR, Marques EF, Di Mascio P, Augusto O. 2013. The carbonylation and covalent dimerization of human superoxide dismutase 1 caused by its bicarbonate-dependent peroxidase activity is inhibited by the radical scavenger tempol. Biochem J 455:37-46.
53. Rak R, Chao DL, Pluta RM, Mitchell JB, Oldfield EH, Watson JC. 2000. Neuroprotection by the stable nitroxide Tempol during reperfusion in a rat model of transient focal ischemia. J Neurosurg 92:646-651.
54. Roberts JC, Francetic DJ. 1993. The importance of sample preparation and storage in glutathione analysis. Anal Biochem 211:183-187.
55. Roos RA. 2010. Huntington's disease: A clinical review. Orphanet J Rare Dis 5:40.
56. Rozas G, Lopez-Martin E, Guerra MJ, Labandeira-Garcia JL. 1998. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 83:165-175.
57. Sakai N, Mizuno R, Ono N, Kato H, Ohhashi T. 2007. High oxygen tension constricts epineurial arterioles of the rat sciatic nerve via reactive oxygen species. Am J Physiol Heart Circ Physiol 293:H1498-H1507.
58. Samuni A, Krishna CM, Mitchell JB, Collins CR, Russo A. 1990. Superoxide reaction with nitroxides. Free Radic Res Commun 9:241-249.
59. Sandhir R, Mehrotra A. 2012. Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: Implications in Huntington's disease. Biochim Biophys Acta 1832:421-430.
60. Sandhir R, Mehrotra A. 2013. Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: Implications in Huntington's disease. Biochim Biophys Acta 1832:421-430.
61. Sandhir R, Mehrotra A, Kamboj SS. 2010. Lycopene prevents 3-nitropropionic acid-induced mitochondrial oxidative stress and dysfunctions in nervous system. Neurochem Int 57:579-587.
62. Sandhir R, Sood A, Mehrotra A, Kamboj SS. 2012. N-acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington's disease. Neurodegener Dis 9:145-157.
63. Saulle E, Gubellini P, Picconi B, Centonze D, Tropepi D, Pisani A, Morari M, Marti M, Rossi L, Papa M, Bernardi G, Calabresi P. 2004. Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. Mol Cell Neurosci 25:9-20.
64. Sedlak J, Hanus L. 1982. Changes of glutathione and protein bound SH-groups concentration in rat adrenals under acute and repeated stress. Endocrinol Exp 16:103-109.
65. Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M, MacDonald ME. 2005. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 14:2871-2880.
66. Shimano Y, Kumazaki M, Sakurai T, Hida H, Fujimoto I, Fukuda A, Nishino H. 1995. Chronically administered 3-nitropropionic acid produces selective lesions in the striatum and reduces muscle tonus. Obes Res 3 (Suppl 5):779S-784S.
67. Sottocasa GL, Kuylenstierna B, Ernster L, Bergstrand A. 1967. An electron-transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J Cell Biol 32:415-438.
68. Soule BP, Hyodo F, Matsumoto K, Simone NL, Cook JA, Krishna MC, Mitchell JB. 2007. The chemistry and biology of nitroxide compounds. Free Radic Biol Med 42:1632-1650.
69. Stahl WL, Smith JC, Napolitano LM, Basford RE. 1963. Brain Mitochondria. I. Isolation of bovine brain mitochondria. J Cell Biol 19:293-307.
70. Szabo C, Ischiropoulos H, Radi R. 2007. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6:662-680.
71. Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH. 1999. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 45:25-32.
72. Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH. 2000. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 47:80-86.
73. Tedeschi H, Harris DL. 1958. Some observations on the photometric estimation of mitochondrial volume. Biochim Biophys Acta 28:392-402.
74. Tunez I, Tasset I, Perez-De La Cruz V, Santamaria A. 2010. 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: Past, present and future. Molecules 15:878-916.
75. Vonsattel JP, DiFiglia M. 1998. Huntington disease. J Neuropathol Exp Neurol 57:369-384.
76. Winkler-Stuck K, Wiedemann FR, Wallesch CW, Kunz WS. 2004. Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients. J Neurol Sci 220:41-48.